Raptor drug slows loss of muscle control in Huntington study

|About: Raptor Pharmaceutical Corp. (RPTP)|By:, SA News Editor

Raptor Pharmaceutical's (RPTP) RP103 treatment for Huntington's disease (HD) achieved the main goal of a Phase 2/3 trial of 96 patients by slowing the loss of muscle control compared with a placebo.

The results are from the first 18 months of the three-year study. (PR)